<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52074">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02064530</url>
  </required_header>
  <id_info>
    <org_study_id>2014/37</org_study_id>
    <nct_id>NCT02064530</nct_id>
  </id_info>
  <brief_title>Postoperative Analgesic Effects of Dexmedetomidine for Transversus Abdominis Plane Block</brief_title>
  <acronym>TAP</acronym>
  <official_title>Postoperative Analgesic Effects of Dexmedetomidine Added to Bupivacaine for Transversus Abdominis Plane Block for Lower Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TC Erciyes University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TC Erciyes University</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the aim of this study is evaluate postoperative analgesic effects of dexmedetomidine added
      to bupivacaine on TAP block in patients undergoing lower abdominal surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TAP block is being used a method of multimodal balanced analgesia reduces postoperative
      pain, opioid requirement after surgery and adverse effect of opioid such as sedation, nausea
      vomiting and ileus. Dexmedetomidine ,an alfa-2 adrenoreceptor agonist,  is being used and
      adjuvant capable of prolonging duration of sensory and motor block on nerve blocks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>opioid consumption</measure>
    <time_frame>postoperative 1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>patient controlled analgesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual analog scale</measure>
    <time_frame>postoperative 1 day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Postoperative Analgesia</condition>
  <condition>Opioid Consumption</condition>
  <arm_group>
    <arm_group_label>bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on TAP block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on TAP block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>serum phsyologic</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>0,9% 21 ml serum physiologic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <arm_group_label>bupivacaine</arm_group_label>
    <other_name>marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <other_name>precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>serum physiologic</intervention_name>
    <arm_group_label>serum phsyologic</arm_group_label>
    <other_name>serum physiologic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA 1-2

          -  18-65 aged

          -  patient undergoing lower abdominal surgery

        Exclusion Criteria:

          -  chronic opioid consumption

          -  bupivacaine and dexmedetomidine allergies

          -  coagulopathy

          -  infection at the needle insertion side

          -  chronic liver and kidney disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Recep Aksu, assoc. prof.</last_name>
    <role>Study Director</role>
    <affiliation>Erciyes universty medicine faculty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gülçin Patmano, resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erciyes universty medicine faculty</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recep Aksu, associated prof.</last_name>
    <phone>+903522076666</phone>
    <phone_ext>24035</phone_ext>
    <email>raksu@erciyes.edu.tr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gülçin Patmano, resident</last_name>
    <phone>+903522076666</phone>
    <phone_ext>20254</phone_ext>
    <email>gulcinpatmano@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erciyes universty</name>
      <address>
        <city>Kayseri</city>
        <state>Melikgazi</state>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recep Aksu, assoc.prof.</last_name>
      <phone>+903522076666</phone>
      <phone_ext>24035</phone_ext>
      <email>raksu@erciyes.edu.tr</email>
    </contact>
    <contact_backup>
      <last_name>Gülçin Patmano, resident</last_name>
      <phone>+905554012878</phone>
      <email>gulcinpatmano@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 16, 2014</lastchanged_date>
  <firstreceived_date>February 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>TC Erciyes University</investigator_affiliation>
    <investigator_full_name>Recep Aksu</investigator_full_name>
    <investigator_title>associated prof.</investigator_title>
  </responsible_party>
  <keyword>TAP block</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>postoperative analgesia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
